Adaptive clinical trials
Adaptive clinical trials can reduce time-to-market and cut development costs
Using adaptive design to optimise product development at the programme and portfolio level
This whitepaper provides insight into adopting an adaptive design strategy at the level of the product portfolio. It has been written to help senior R&D decision-makers understand the critical role of adaptive design in portfolio decision-making and in appreciating the value that this approach can bring.
Latest on adaptive trial design
If you would like to receive our adaptive trials email updates, including the latest on adaptive trial design, visit our preference centre and select adaptive design.
Adaptive trials blogs and media articles
-
Using Bayesian-based, model-assisted designs to improve dose selection in early phase oncology trials
As oncology therapeutics and early phase design models evolve, sponsors will benefit from working with a partner experienced in innovative adaptive designs for phase 1 and 2 oncology trials.
-
Blog: An introduction to applications of adaptive design
An adaptive design clinical trial can help to create a stronger value proposition for your product and give you a competitive edge, by reducing development costs andaccelerating time-to-market.
-
Media article: Adaptive design years later: What have we Learned?
Teams at the forefront of adative design are looking to technological breakthroughs, for example by applying quantum computing to machine learning models to predict clincial trial outcomes. Such initiiatives will redefine how sponsors use data and adaptive design, ushering in a new era of clinical trials.
-
Media article: Adaptive designs: Smarter development programmes for oncology
The different types of adaptive trial designs that have been deployed in oncology trials to good effect, and discusses how they have changed the development paradigm.
